The applications of Targeted Delivery for Gene Therapies in Hearing Loss
J Drug Target. 2023 May 21:1-22. doi: 10.1080/1061186X.2023.2216900. Online ahead of print.
Gene therapies are becoming more abundantly researched for use in a multitude of potential treatments, including for hearing loss. Hearing loss is a condition which impacts an increasing number of the population each year, with significant burdens associated. As such, this review will present the concept that delivering a gene effectively to the inner ear may assist in expanding novel treatment options and improving patient outcomes. Historically, several drawbacks have been associated with the use of gene therapies, some of which may be overcome via targeted delivery. Targeted delivery has the potential to alleviate off-target effects and permit a safer delivery profile. Viral vectors have often been described as a delivery method, however, there is an emerging depiction of the potential for nanotechnology to be used. Resulting nanoparticles may also be tuned to allow for targeted delivery. Therefore, this review will focus on hearing loss, gene delivery techniques and inner ear targets, including highlighting promising research. Targeted delivery is a key concept to permitting gene delivery in a safe effective manner, however, further research is required, both in the determination of genes to use in functional hearing recovery and formulating nanoparticles for targeted delivery.
PMID:37211674 | DOI:10.1080/1061186X.2023.2216900
Journal of drug targeting
DATE – PUBLISHED:
Mon, 22 May 2023 06:00:00 -0400
DATE – DOI:
DATE – ADDED:
LINK – PUBMED:
LINK – DOI:
LINK – PUBLISHER:
Hearing Loss Treatment Report, Urgent Research, 2023-05-22T10:38:48+00:00, https://www.hearinglosstreatmentreport.com.